Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical is poised for growth, as evidenced by the significant revenue increase of 19% year-over-year for its Jornay PM product, bringing in $42 million, which outperformed market expectations. The company's market share has also improved, rising to 23.4% from approximately 17%, with prescriptions increasing by 20% year-over-year, indicating strong demand across both pediatric and adult demographics. Furthermore, the expansion of the sales force and marketing efforts, alongside improvements in gross-to-net ratios, are expected to sustain revenue growth, particularly for Jornay PM as it becomes a cornerstone of the company’s future performance.

Collegium Pharmaceutical faces significant risks that contribute to a negative outlook on its stock, primarily driven by anticipated declines in sales across key products, including Xtampza ER and Belbuca, as well as challenges within the broader Nucynta franchise. The company's guidance for 2026 suggests a low-single digit year-over-year decline in pain portfolio sales, projecting approximately $620 million, a decrease from the estimated $632 million in 2025. Additionally, there are critical concerns regarding potential competition from generics, varying reimbursement conditions, and execution risks, all of which could adversely affect commercialization efforts and overall profitability.